Celsion’s OVATION 1 Study with GEN-1 in Ovarian Cancer Shows Strong Progression-Free Survival Treatment Effect Utilizing Medidata Synthetic Control Arm
March 26, 2020 08:00 ET
|
Celsion CORP
Hazard Ratio of 0.53 for PFS in the Phase I Intent-To-Treat Population Synthetic Randomization Provides Means to Evaluate Strategies to Accelerate GEN-1 Clinical Program for Newly Diagnosed Stage...